Adaptive BiotechnologiesADPT
Market Cap: $628M
About: Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
Employees: 709
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
53% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 45
17% more capital invested
Capital invested by funds: $459M [Q1] → $538M (+$78.8M) [Q2]
2.22% more ownership
Funds ownership: 98.63% [Q1] → 100.85% (+2.22%) [Q2]
7% less funds holding
Funds holding: 188 [Q1] → 174 (-14) [Q2]
37% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 38
73% less call options, than puts
Call options by funds: $88K | Put options by funds: $323K
100% less funds holding in top 10
Funds holding in top 10: 2 [Q1] → 0 (-2) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
JP Morgan Rachel Vatnsdal 52% 1-year accuracy 14 / 27 met price target | 41%upside $6 | Overweight Maintained | 2 Aug 2024 |